Prognostic value of FBXO39 and ETS-1 but not BMI-1 in Iranian colorectal cancer patients by Motalebzadeh, J. et al.
Asian Pacific Journal of Cancer Prevention, Vol 19 1357
DOI:10.22034/APJCP.2018.19.5.1357
FBXO39 and ETS-1 Potentialfor Prognostic Markers in Colorectal Cancer Patients 
Asian Pac J Cancer Prev, 19 (5), 1357-1362 
Introduction
Colorectal cancer (CRC) is one of the prevalent cancers 
worldwide. Studies have shown that cancer prevalence in 
Iran is higher than the global rate (Esna-Ashari et al., 
2008; Moradi et al., 2009). Despite recent progression 
in diagnosis and treatment of cancer, it is still one of the 
health problems in the world, and therefore requires further 
studies. In this regards, study of the expressions of the 
genes involved in CRC is rather important.
Currently The Cancer Genome Atlas (TCGA) research 
has categorized the types of cancer based on some genetic 
markers (Verhaak et al., 2012; Marisa et al., 2013). 
For example studies have shown about 90% of CRC 
is involved in alteration of genes comprised with Wnt 
signaling pathway (Najdi et al., 2011). However, more 
studies are needed to introduce more markers particulary 
for CRC.
One of the specific tumor markers is Cancer/testis 
antigens are considered as a group of specific tumor 
markers. CRC tumors are known as the tumors in which 
the expression of the genes of the Cancer/testis antigens 
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family is limited (Caballero and Chen, 2009). Song 
and colleagues successfully introduced FBXO39 gene 
(located on 17p31.1) as a Cancer/testis antigen (Song et 
al., 2011) which its expression could be detected in some 
CRC samples.
ETS-1 is located on chromosome 11q24.3 and belongs 
to the ETS family which are a group of the transcription 
factors. Studies have shown the over-expression of 
ETS-1 is associated with progression of various cancers 
(Dittmer, 2003; Verschoor et al., 2010). ETS-1 expression 
is association with tumor invasion and metastasis (Pei 
et al., 2005). This transcription factor is involved in the 
control of tumor metastases by targeting crucial genes 
which role in cancer invasion and metastasis such as 
matrix metalloproteinases and integrin (Rothhammer 
et al., 2004; Lefter et al., 2009). Also studies showed 
the over-expression of ETS-1 is associated with poor 
prognosis in patients with breast (Span et al., 2002) and 
ovarian cancer (Takai et al., 2002). 
BMI-1 belongs to the Polycomb repressor complex 
1 and is located on chromosome10p11 (Bhattacharya et 
al., 2015). This gene as a gene regulatory factor plays 
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as an oncogene in cell proliferation and cell movement 
(Jacobs et al., 1999; Glinsky et al., 2005). The importance 
of BMI-1 gene as a regulator factor in cell proliferation 
has been shown in early stages of CRC (Yu et al., 
2012). BMI-1 is mostly expressed in primary stage of 
neuroblastoma compare to the advance stage of the disease 
(Nowak et al., 2006). Also this gene is associated with 
advanced stage of prostate (van Leenders et al., 2007) 
and breast cancer (Guo et al., 2011).
For years our research team has been investigating 
a panel of genes to find suitable dignsotic/prognostic 
markers for colorectal and breast cancer (Motalebzadeh et 
al., 2017). The three above genes were selected and their 
expression were detected at the mRNA level. We wished 
to see whether or not they could be used as potential 
diagnostic/prognostic biomarkers. 
Materials and Methods
Patients and tumors characteristics
Thirty six patients with locally advanced CRC 
between 2011-2013 years admitted to Hazrat-e-rasoul 
hospital-Tehran were enrolled in this study. The heriditary 
CRC cases such as FAP, Lynch etc, were excluded. Only 
Iranian CRC pateints were enrolled in this investigation.
Fresh tissues (tumor and normal tissue adjacent to the 
tumor) were collected by the clinicians in separate 
sterile tubes. Tissue samples were frozen and stored at 
-70°C. The pathological information of all patients was 
obtained from pathology department of Hazrat-e-rasoul 
Hospital. Staging of CRC was performed according to 
the International Union against Cancer (UICC) which is 
based on (AJCC-TNM) classification (Edge and Compton, 
2010). The patients were followed up and except one 
patient, others are all still alived.
The patients and tumor characteristics, gathered from 
the pathology reports. The minimum and maximum age 
of patients were 29 and 79 years old respectively with 
the average age 52.5 years. The pateints were classified 
in four groups according to the tumor size: less than 5cm, 
between 5 and 8cm, between 8 and 10cm and larger than 
10cm. Pateints were categorized in three groups based on 
lymph node involvment: N0 ( no lymph node involved), 
N1(1-4 lymph nodes involved) and N2 (more than 4 lymph 
nodes involved). Ten out of thirty six pateints had long 
distance metastasis (Table 1).
RNA extraction and cDNA synthesis
After confirming histological diagnosis of all samples, 
RNA was isolated from 100 mg tissue with using Tripure 
Isolation Reagent (Roche Applied Sciences, Indianapolis, 
USA). For cDNA synthesis, RNAs were synchronized 
and according to the concentration of RNAs first-strand 
cDNA was synthesized as the manufacturer’s protocol 
(Thermo scientific kit).
RT-PCR and Real-time RT-PCR
In this study, the expression pattern of FBXO39 and 
ETS-1 genes were investigated in CRC tumor and adjacent 
normal tissues (as control) using RT-PCR. Accuracy of 
all cDNA samples were checked using GAPDH gene as 
an internal control. The total volume of the PCR reaction 
was 25 μL for each reaction containing PCR buffer, MgCl2 
(1.6 mM), dNTPs (120 μm), Primers (0.4 μm), Enzyme 
(1 U/25 μl) and template cDNA.
To evaluate BMI-1 gene expression level by real-time 
RT-PCR using a Rotor gene 6,000 (Corbett Research 
Pty. Ltd., Australia) system with Fast-Start DNA Master 
SYBR-Green I kit (YTA, Iran) using GAPDH as an 
internal control gene. The total volume of the PCR reaction 
for all samples was 10 μL contained 5 μl SYBR Green 
PCR master mix, 0.3 μl of each primer (10 μmol/l) and 1 
μl template (400 ng/μl). The PCR cycles for each genes 
are summerized in Table 2.
Primers were desighned according to exon–exon 
junction pattern and specifically for the mentioned three 
gene mRNAs. Primers sequences are shown in table 3. 
Samples for no-template were also included in each test 
to detect any contamination. 
Statistical analysis
The data were analyzed using the Statistical Package 
for Social Sciences (SPSS version 19) software. 
RT-PCR data were analyzed using the chi-square test. 
Non-parametrics test were used for relative quantification 
of the gene expression. For comparison of means 
between two groups Mann WithneyU test was used and 
for comparison of means among three or more groups 
Krus-kal-Wallis test was used. A p-value of <0.05 were 
considered statistically significant.
Results
FBXO39 expression
In this study the relation between FBXO39 gene 
expression and the clinical risk factors in patients with 
CRC was examined. Testis tissue was used as a positive 
control sample. The expression pattern of FBXO39 in 
six CRC samples on gel electerophoresis was shown in 
Figure 1.
Our results indicated the expression pattern of 
FBXO39 gene was restricted to tumor cells and the gene 
expression was not observed in the adjacent normal tissues 
(Table 4). This gene was expressed in 64% of all tumoral 
tissues. Although the expression of this gene was detected 
in all stage-0 tumor samples but there is no significant 
relation between the gene expression pattern and stages 
of CRC. As shown in table 5 a significant relation was 
observed between FBXO39 gene expression and patients 
lymph node status (P<0.05).
ETS-1 expression
ETS-1 gene is mostly expressed in CRC tissues (66% 
of all tumor tissues) with p-value=0.03 compare to the 
adjacent normal tissues (Table 4). The expression pattern 
of ETS-1 in five CRC samples was shown in Figure 1. 
The expression of ETS-1 in all CRC samples showed 
there was a significant relationship between the gene 
expression and tumor size and lymph node involvement 
with p-value=0.039 and p-value=0.009 respectively. In 
all metastatic cases ETS-1 was expressed while in 62% 
of non metastastatic pateints the expresion of this gene 
was detected (not significant, P>0.05). Also there was 
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Among all the pateints enrolled in this study only 
one case passed away. Both ETS-1 and FBXO39 had 
expression in tumarl tissue of this pateint. In addition BMI-
1 expression in tumoral tissue of this pateint was slightly 
higher than mean expresion but of course statistically can 
not be interpreted.
not a significant relation between ETS-1 expression and 
patient’s gender and age.
BMI-1 gene expression
Our studies on BMI-1gene expression level using 
real time RT-PCR showed there was no significant 
(p-value=0.708) difference between the gene expression 
in normal tissues and CRC tumor tissues (Table 4). Also 
we found no association between the gene expression 
level and clinicopathological features. Comparison of the 
expression level of BMI-1 mRNA in tumor and normal 
tissues was indicated in Figure 3.
All above results are summerized and pressented in 
Table 4 and 5.
FBXO39, ETS-1 and BMI-1 expression and survival 
characteristics Groups Number Percent
Total patients 36 100
Age >52 20 56%
<52 16 44%
Gender Male 16 43%
Female 20 57%
Tumor size(cm) <5 18 50%
5-8 13 36.10%
8-10 3 8.30%
>10 2 5.60%
Lymph node N0 14 38.90%
N1 15 41.70%
N2 7 19.40%
Stage 0 3 8.30%
I 3 8.30%
II 7 19.40%
III 13 36.10%
IV 10 27.80%
Grade I 9 25%
II 18 50%
Un-known 9 25%
Metastasis M0 (no metastasis) 26 27%
M1 (metastasis) 10 73%
Table 1. The Clincopathological Information of Patients
Gene Number 
of Cycle
Denaturation Annealing Extention
FBXO39 35 Time: 40s
Temperature: 
94°C
Time: 40s
Temperature: 
59° C
Time: 30s
Temperature: 
72° C
ETS-1 35 Time: 30s
Temperature: 
94° C
Time: 30s
Temperature: 
61° C
Time: 45s
Temperature: 
72° C
BMI-1 45 Time: 20s
Temperature: 
95° C
Time: 15s
Temperature: 
63° C
Time: 20s
Temperature: 
72° C
Table 2. The PCR cycles for FBXO39, ETS-1 and BMI-
1. RT-PCR was used for amplificarion of FBXO39 and 
ETS-1. Real time RT-PCR was used for amplification of 
BMI-1 mRNA expression level.
Figure 1. The Expression Pattern of FBXO39 Gene on 
1.5% Agarose Gel. The PCR reaction product length for 
FBXO39 is 265 bp. In this figure the result of RT-PCR 
for six colorectal tumor samples are shown. Testis tissue 
was used as a positive control sample. N=Negative 
control, P, Positive control; M, Molecular marker (50 
bp).
Figure 2. The Expression Pattern of ETS-1 Gene on 
1.5% Agarose Gel. The PCR reaction product length for 
ETS-1 gene is 300 bp. In this figure the result of RT-
PCR for five CRC samples are shown. Testis tissue was 
used as a positive control sample. N, Negative contro; P, 
Positive control; M, Molecular marker (100 bp).
Figure 3. Mean Expression Level of BMI-1 Gene 
in Colorectal Tumor and Normal Tissues. Relative 
quantification of BMI-1 using GAPDH as internal 
control gene indicated there was no significant diffence 
in BMI-1 gene expression between tumor and normal 
tissues (p-value=0.708).
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Discussion
One of the most common causes of the mortality in 
the world is cancer. In spite of progressions/advancement 
in CRC treatments, the clinical outcome is far away from 
expectation. Some of the main reasons are late diagnosis, 
lack of suitable markers for early detection, prognosis and 
prediction to treatment. 
Cancer biomarkers are discussed as molecular and 
genetic alterations such as DNA methylation, mutation, 
copy number and gene expression (Verhaak et al., 2012; 
Marisa et al., 2013). In this study we aimed to analyze 
FBXO39, ETS-1, and BMI-1 genes expression to find 
the posible value of them in diagnosis or prognosis in 
CRC patients.
Cancer/testis antigens (CTAs) are a group of antigens 
in many kinds of cancerous tissues and normal testis 
tissue also this group of antigens exist in spleen tissue 
(Old and Chen, 1998). Song and colleagues introduced 
FBXO39 gene as a new Cancer/testis antigene. They 
found FBXO39 gene severly expressed in 22 out of 57 
samples of colon cancer tissues (Song et al., 2011). In a 
study by Tarnowski et al., (2016) they found this gene was 
overexpressed in colon cancer compared to the normal 
tissues, while they found no association between the gene 
expression and tumor progression. In the present study 
we investigated the expression of FBXO39 gene in CRC 
and adjacent normal tissues by RT-PCR. FBXO39 gene 
expressionwas observed in 64% of all tumoral tissues. 
The expression of this gene was seen in all CRC stage-0 
samples.
Thus, due to the lack of FBXO39 gene expression 
in normal tissue and the expression of the gene in early 
stage cancerous tissues, the expression of this gene can 
be considered as a possible diagnostic biomarker for CRC 
although further study required to completely confirm 
this data. Furthermore, this study was also conducted 
to investigate the association between the expression of 
this gene and clinicopathological features. We found a 
significant relation between FBXO39 gene expression 
and the lymph node involvement.
ETS-1 is known as a transcription factor gene 
that plays a role in tumor invasion and angiogenesis. 
Nakayama et al., (2001) demonstrated that ETS-1 gene 
was not expressed in any of 15 healthy colonic mucosa 
tissues, while in our study the expression of ETS-1 
detected in 45% of all normal adjacent tissues and 66% of 
all CRC tumors. Peng and colleagues indicated that ETS-1 
was expressed in 57.59% of CRC tissues (significantly 
higher than its expression in normal tissue). 
They found that there was a significant association 
between gene expression and cancer stage (Peng et al., 
2014). Also in another study by Tokuhara et al., (2002) 
ETS-1 gene expression was associated with metastasis to 
lymph nodes in CRC. We found that there was a significant 
relationship between the gene expression and tumor 
size and lymph node involvement with p-value=0.039 
and p-value=0.009 respectively. In all metastatic cases 
ETS-1 was expressed. There was not a significant relation 
between ETS-1 expression and patients’ gender and age
The other candidate gene, BMI-1, initialy was 
examined by RT-PCR but since we found that this 
gene was expressed in all tumor and normal tissues, we 
employed real time RT-PCR to quantify the expression 
level of BMI-1 mRNA in all samples.
The results of a study by Kim et al., (2004) on BMI-1 
gene expression in CRC tissue indicated increased mRNA 
levels by 2 to 3 fold compared to normal tissue. Also Lin 
et al., (2008) showed significantly increased expression 
of BMI-1 gene in CRC tumoral tissues and indicated a 
significant relation of the gene expression with distant 
Gene Sequence Length Product length
FBXO39 F 5'-GCTGCTTGAGAACTTGTGTGA-3' 21 265 bp
R 5'-GGGTCTCATTGAACAGTCTGG-3' 21
ETS-1 F 5'-CCTATCCAGAATCCCGCTAT-3' 20 300 bp
R 5'-CCCCGAGTTTACCACGAC-3' 18
BMI-1 F 5'-ATACCTGGAGAAGGAATGGTC-3' 21 210 bp
R 5'-GAGGAGACTGCACTGGAGTA-3' 20
GAPDH F 5'-GCAGGGGGGAGCCAAAAGGGT-3' 21 219 bp
R 5'-TGGGTGGCAGTGATGGCATGG-3' 21
Table 3. Sequences of the Primers
Gene p-value Significancy
FBXO39 <0.01 Significant at 0.01 level
ETS-1 0.03 Significant at 0.05 level
BMI-1 0.708 Not  Significant
Table 4. Comparison of FBXO39, ETS-1 and BMI-1 
Expression between CRC Tumor and the Adjacent 
Normal Tissues
Pathological characteristics FBXO39 
P-value
ETS-1 
P-value
BMI-1 
P-value
Patients’gender 0.608 0.197 0.741
Patients’ age 0.958 0.1 0.072
Tumor size 0.764 0.039* 0.949
Lymph node 0.040* 0.009* 0.907
Stage 0.209 0.197 0.928
Grade 0.341 0.409 0.523
Metastasis 0.608 0.197 0.741
Table 5. The Relation between the Gene Expression 
and Clinicopathological Characteristics in Patients with 
CRC
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metastasis.
In contrast with the Lin study on BMI-1 gene, we 
found no difference between the gene expression in normal 
tissues and CRC tumor tissues. Furthermore, we found 
no association between BMI-1 gene expression level and 
clinicopathological features
The summary of association between pathological 
features and genes expression is as follow:
A) Age: The risk of CRC increases with aging (Amersi 
et al., 2005). The analysis of our data showed that there 
was no association between the expression of any of these 
genes and patient’s age .
B) Tumor size: Studies have shown that an increase 
in tumor size relates to an increased risk of recurrence/
metastasis in the most cancers. In our study there was a 
significant association between ETS-1 gene expression 
and tumor size , while no association was found with 
metastasis. 
C) Lymph node involvement: One of the important 
factors in determining prognosis in CRC is lymph node 
involvement. In the present study data analysis showed 
that FBXO39 and ETS-1 genes expression were correlated 
with lymph nodes involvement.
D) Stage: Cancer staging describes the size of tumor 
and where it has spread. Our results showed there was no 
significant relation between any of these genes expression 
and CRC staging.
E) Histological grade: Tumor grade is also an important 
prognostic variable. In our study there was no association 
between any of these genes and histological grade.
In conclusion, bases on our study on these three 
candidate genes in CRC cases we indicated significant 
association between FBXO39 and ETS-1 genes expressions 
and lymph node involvement. Since the involvement of 
lymph nodes can induce metastasis in patients, it is 
possible that the expression of FBXO39 and ETS-1 genes 
are an alarm for the occurrence of metastasis and thus 
may be a potential prognostic biomarkers. Furthermore, 
FBXO39 gene expression could be a candidate for early 
detection of CRC. Howevere, due to the small numbers of 
the samples studied, further investigation on more CRC 
samples are needed to be able to draw a robust conclusion.
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